Microviable announces 1.5 million € investment to advance the company´s microbiota-derived biotherapeutic products.

2022-04-19T20:48:43+02:0019 de April de 2022|

Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]